Predictors of occurrence complications in patients with newly diagnosed atrial fibrillation at 6-month follow
Article Sidebar
Main Article Content
Abstract
The aim – to compare concomitant diseases, myocardial structure and function, clinical symptoms and course of arrhythmia in patients with first diagnosed atrial fibrillation (FDAF) with and without severe cardiovascular complications at 6-month follow-up.
Material and methods. In total, the study group included 124 patients. We evaluated symptoms, cardiovascular
disease, risk factors, comorbidities, renal and thyroid function, carbohydrate and lipid metabolism, results of echocardiography, background therapy. Overall, the 6-month observation period in 25 (20.1 %) patients registered cases of death and serious cardiovascular events. For comparison of clinical-anamnestic and instrumental characteristics, groups of patients with complications (n=25) and without complications (n=99) were formed.
Results. The features of the group of patients with complications were the senior age, as well as a significantly greater initial frequency of heart failure, previous heart attacks and strokes, and diabetes mellitus. The frequency of manifestation of hypertension and coronary heart disease (except post-infarction cardiosclerosis) did not differ in comparable groups. The likelihood of complications also depended on the form of the FDAF. In particular, complications were significantly more often registered in patients with a permanent form of AF. Patients from the complicated group were characterized by more pronounced changes in the structural and functional state of the myocardium: larger left ventricular myocardium mass index and end-diastolic volume, lower left ventricular ejection fraction, significantly more often they detected moderate or severe mitral and tricuspid regurgitation.
Conclusions. Independent predictors of adverse prognosis at 6-month follow proved to be heart failure III–IV functional class NYHA, mitral regurgitation II–III degree. Comparable groups did not differ regarding severity of clinical symptoms by EHRA scale.
Article Details
Keywords:
References
Гржибовский А.М. Анализ номинальных данных (независимые наблюдения) // Экология человека.– 2008.– № 6.– C. 58–68.
Діагностика та лікування фібриляції передсердь. Рекомендації робочої групи з порушень серцевого ритму Асоціації кардіологів України. – К., 2011. – 22 с.
Жарінов О.Й., Надорак О.П., Єпанчінцева О.А. та ін. Предиктори небезпечних для життя ускладнень після аортокоронарного шунтування у пацієнтів з післяопераційною фібриляцією передсердь // Укр. кардіол. журн.– 2014.– № 3.– C. 61–67.
Aksnes T.A., Schmieder R.E., Kjeldsen S.E. et al. Impact of new-onset diabetes mellitus on development of atrial fibrillation and heart failure in high-risk hypertension (from the VALUE Trial) // Amer. J. Cardiol.– 2008.– Vol. 101 (5).– P. 634–638.
ACCF/ASE/ACEP/ASNC/SCAI/SCCT/SCMR 2007 appropriateness criteria for transthoracic and transesophageal echocardiography // J. Amer. Soc. Echocardiogr.– 2007.– Vol. 20.– P. 787–805.
Azoulay L., Dell’Aniello S., Simon T.A. et al. Initiation of warfarin in patients with atrial fibrillation: early effects on ischaemic strokes // Eur. Heart J.– 2014.– Vol. 35 (28).– P. 1881–1887.
Bassand J.–P., Accetta G., Camm A.J. et al. Two-year outcomes of patients with newly diagnosed atrial fibrillation: results from GARFIELD-AF// Eur. Heart J.– 2016.– Vol. 37 (38).– P. 2882–2889.
Boriani G., Laroche C., Diemberger I. et al. Glomerular filtration rate in patients with atrial fibrillation and 1-year outcomes // Sci Rep.– 2016.– Vol. 6.– P. 30271.
Christiansen C.B., Gerds T.A., Olesen J.B. Atrial fibrillation and risk of stroke: a nationwide cohort study // Europace.– 2016.– Vol. 18.– Р.1689–1697.
Conen D., Chae C.U., Glynn R. J. et al. Risk of death and cardiovascular events in initially healthy women with new-onset atrial fibrillation // JAMA.– 2011.– Vol. 305 (20).– P. 2080–2087.
KDIGO 2012 Clinical Practice Guideline for the Evaluation and Management of Chronic Kidney Disease // Official J. Intern. Soc. Nephrology.– 2013.– Vol. 27.– P. 126–150.
Kirchhof P., Benussi S., Kotecha D. et al. ESC Guidelines for the management of atrial fibrillation developed in collaboration with EACTS: The Task Force for the management of atrial fibrillation of the European Society of Cardiology (ESC) Developed with the special contribution of the European Heart Rhythm Association (EHRA) of the ESCEndorsed by the European Stroke Organisation (ESO) // Eur. Heart J.– 2016.– Vol. 37.– P. 2893–2962.
Lang R., Badano L.P., Mor-Avi V. et al. Recommendations for Cardiac Chamber Quantification by Echocardiography in Adults: An Update from the American Society of Echocardiography and the European Association of Cardiovascular Imaging // J. Am. Soc. Echocardiogr.– 2015.– Vol. 28.– P. 1440–1457.
Levey A.S., Stevens L.A., Schmid C.H. et al. A new equation to estimate glomerular filtration rate // Ann. Intern. Med.– 2009.– Vol. 150.– P. 604–612.
Murin J., Naditch-Brûlé L., Brette S. Clinical characteristics, management, and control of permanent vs. nonpermanent atrial fibrillation: insights from the RealiseAF Survey // PLoS One.– 2014.– Vol. 9 (1).
Piepoli M.F., Hoes A.W., Agewall S. et al. 2016 European Guidelines on cardiovascular disease prevention in clinical practice The Sixth Joint Task Force of the European Society of Cardiology and Other Societies on Cardiovascular Disease Prevention in Clinical Practice (constituted by representatives of 10 societies and by invited experts) // Eur. Heart J.– 2016.– Vol. 37.– P. 2315–2381.
Ponikowski P., Voors A.A., Anker S.D. et al. 2016 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure. The Task Force for the diagnosis and treatment of acute and chronic heart failure of the European Society of Cardiology (ESC) // Еur. Heart J.– 2016.– Vol. 37.– P. 2129–2200.
Schnabel R.B., Yin X., Gona P. et al. Fifty-year trends in atrial fibrillation prevalence, incidence, risk factors, and mortality in the community // Lancet.– 2015.– Vol. 386.– P. 154–162.
Schnabel R.B., Wilde S., Wild S.P. et al. Atrial fibrillation: its prevalence and risk factor profile in the German general // Dtsch. Arztebl. Int.– 2012.– Vol. 109.– P. 293–299.
Swedberg K., Olsson L.G., Charlesworth A. et al. Prognostic relevance of atrial fibrillation in patients with chronic heart failure on long-term treatment with betablockers: results from COMET // Eur. Heart J.– 2005.– Vol. 26.– P. 1303–1308.
The Task Force for the management of atrial fibrillation of the European Society of Cardiology. Guidelines for the management of atrial fibrillation // Eur. Heart J.– 2010.– Vol. 31.– P. 2369–2429.
Yamauchi T., Sakata Y. Miura Masanobu prognostic impact of new-onset atrial fibrillation in patients with chronic heart failure – a report from the CHART-2 Study // Circ. J.– 2016.– Vol. 80.– P. 157–167.